Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$26.12 - $34.07 $1.01 Million - $1.32 Million
38,776 Added 34.69%
150,558 $5.13 Million
Q1 2024

May 14, 2024

SELL
$26.64 - $40.31 $2.59 Million - $3.93 Million
-97,394 Reduced 46.56%
111,782 $3.93 Million
Q4 2023

Feb 14, 2024

BUY
$19.95 - $31.0 $3.34 Million - $5.2 Million
167,606 Added 403.19%
209,176 $6.04 Million
Q3 2023

Nov 14, 2023

SELL
$21.33 - $59.42 $23.9 Million - $66.5 Million
-1,119,047 Reduced 96.42%
41,570 $952,000
Q2 2023

Aug 15, 2023

BUY
$34.33 - $62.11 $37.7 Million - $68.1 Million
1,096,832 Added 1719.58%
1,160,617 $66.5 Million
Q1 2023

May 15, 2023

SELL
$26.01 - $48.69 $102,661 - $192,179
-3,947 Reduced 5.83%
63,785 $2.4 Million
Q4 2022

Feb 14, 2023

BUY
$24.14 - $30.37 $380,277 - $478,418
15,753 Added 30.31%
67,732 $1.81 Million
Q3 2022

Nov 15, 2022

SELL
$22.23 - $33.37 $752,774 - $1.13 Million
-33,863 Reduced 39.45%
51,979 $1.47 Million
Q2 2022

Aug 15, 2022

BUY
$19.74 - $43.01 $803,575 - $1.75 Million
40,708 Added 90.19%
85,842 $1.86 Million
Q1 2022

May 13, 2022

BUY
$36.25 - $52.02 $813,232 - $1.17 Million
22,434 Added 98.83%
45,134 $1.81 Million
Q4 2021

Feb 14, 2022

SELL
$43.27 - $65.72 $25,962 - $39,432
-600 Reduced 2.58%
22,700 $1.08 Million
Q2 2021

Jul 30, 2021

BUY
$45.13 - $64.99 $437,761 - $630,403
9,700 Added 71.32%
23,300 $1.34 Million
Q1 2021

May 06, 2021

SELL
$29.77 - $84.85 $107,172 - $305,460
-3,600 Reduced 20.93%
13,600 $861,000
Q4 2020

Feb 08, 2021

SELL
$25.66 - $34.55 $2,566 - $3,454
-100 Reduced 0.58%
17,200 $577,000
Q3 2020

Nov 12, 2020

SELL
$22.51 - $30.11 $24,761 - $33,121
-1,100 Reduced 5.98%
17,300 $473,000
Q2 2020

Aug 13, 2020

BUY
$12.65 - $29.57 $99,935 - $233,603
7,900 Added 75.24%
18,400 $498,000
Q1 2020

May 14, 2020

BUY
$10.84 - $20.85 $113,820 - $218,925
10,500 New
10,500 $154,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.